HOME >> MEDICINE >> NEWS
Sirolimus-eluting Coronary Stent outperforms paclitaxel eluting stent in seven study meta-analysis

WASHINGTON, D.C. (October 20, 2005) The most comprehensive and detailed analysis conducted to date of drug-eluting stent comparative trials shows a marked difference in the rate of target lesion revascularization (TLR) and restenosis in patients who received the CYPHER Stent vs. the Taxus Stent in seven studies totaling 4,214 patients. The CYPHER Stent vs. Taxus Stent meta-analysis was presented today to cardiologists and other attendees from throughout the world during the Cardiovascular Research Foundation's (CRF) 17th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

The purpose of this meta-analysis was to systematically review randomized comparative DES trials and obtain a more precise understanding of the true treatment effect of the CYPHER Stent and the Taxus Stent than any individual trial can provide.

Stephan Winndecker, M.D. and Peter Juni, M.D. of University Hospital Bern in Switzerland conducted a thorough review of clinical results from the head-to-head trials, analyzed extended patient follow-up data and initiated an extensive review of publications and information on these trials, many of which have been published in major medical journals.

The meta-analysis of the seven head-to-head drug-eluting stent trials TAXI, SIRTAX, ISAR DESIRE, ISAR DIABETES, REALITY, CORPAL and BASKET - demonstrated that the CYPHER Stent more effectively reduced the need for re-treatment, target lesion revascularization, by about 30% compared to Taxus Stent-treated patients.

"The benefit of the CYPHER Stent in reducing the need for re-treatment was observed in multiple patient and lesion types in this analysis," stated Dennis Donohoe, M.D., vice president of worldwide clinical research and regulatory affairs for Cordis Corporation. "This rigorously conducted meta analysis establishes the highest level of scientific evidence of the relative performance of these two drug-eluting stents. The CYPHER Stent's strong
'"/>

Contact: Todd Ringler
todd.ringler@edelman.com
781-599-7542
Edelman Public Relations
20-Oct-2005


Page: 1 2

Related medicine news :

1. CYPHER Sirolimus-eluting Coronary Stent benefits from clinical success, worldwide growth in 2005
2. Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery
3. Coronary surgery -- keeping the way clear
4. Coronary heart disease deaths in Ireland have halved in 15 years
5. Stenting of abdominal arteries offers welcome relief for intestinal angina
6. Stent-graft procedure improves outcomes of carotid aneurysm repair
7. Study finds patients with chronic total occlusions benefit from the CYPHER Stent
8. New study results suggest better outcomes with the CYPHER Stent than brachytherapy
9. Stents that release medication appear more effective than traditional stents
10. Drug-eluting stent controversy explored in the American Heart Hospital Journal
11. Drug eluting nanostructured coatings enable targeted drug therapy for orthopedic patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
Cached News: